Dutch intranasal vaccine developer Mucosis has received €3.7 million from the Wellcome Trust for clinical development of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. The money will be used to fund a Phase 1 dose-finding study and a Phase 2 challenge study conducted by researchers from the National Heart & Lung Institute, Imperial College London.
The company also said that current investors are providing an additional €2m in equity financing, which will be used for GMP manufacturing and for preparation of regulatory submission materials.
Mucosis CEO Tom Johnston commented, “We are delighted that the Wellcome Trust has recognized the potential of SynGEM to address the global health challenge of combatting RSV infections by contributing funds to this program. SynGEM has performed exceptionally well in pre-clinical trials and we are pleased to have secured additional funding to more quickly advance a needle-free vaccine for RSV into the clinic.”
Read the Mucosis press release.
